argenx initiates Phase II trial of ARGX-113 to treat pemphigus vulgaris

Belgium-based biotechnology firm argenx has initiated a Phase II clinical trial of its investigational agent, ARGX-113, to treat patients with pemphigus vulgaris (PV).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

Abstract Dermatology was consulted in the care of a 58-year-old man with a history of paranoid schizophrenia, neuroleptic malignant syndrome, a positive purified protein derivative test, and a lack of bathing for approximately 4 years who had been admitted to the hospital because of thick, crusted lesions over an increasing portion of his body. Admitted involuntarily, he was disinterested in the history, physical examination, and diagnostic testing. Comorbid schizophrenia presented a unique challenge because he was unable to participate in his care effectively. His story was told through caregivers. Although mostl...
Source: Skinmed - Category: Dermatology Authors: Tags: Skinmed Source Type: research
We report a case of PV with esophageal involvement in a 53-year-old woman who sought medical care, complaining of diffuse painful lesions in the oral cavity for approximately 1 month, with no improvement with nystatin. Upper digestive endoscopy (UDE) was performed with findings of vesiculobullous lesions in the proximal and middle esophagus, which were biopsied and for which histopathology confirmed PV in the esophageal mucosa. We draw attention to UDE as important for the diagnosis, and it should be indicated in patients with vesiculobullous lesions of the mouth, especially if there are esophageal complaints.Case Rep Gast...
Source: Case Reports in Gastroenterology - Category: Gastroenterology Source Type: research
AbstractThe skin is the largest organ of the body, at the boundary with the outside environment. Primarily, it provides a physical and chemical barrier against external insults, but it can act also as immune organ because it contains a whole host of immune-competent cells of both the innate and the adaptive immune systems, which cooperate in eliminating invading pathogens following tissue injury. On the other hand, improper skin immune responses lead to autoimmune skin diseases (AISD), such as pemphigus, bullous pemphigoid, vitiligo, and alopecia. Although the interplay among genetic, epigenetic, and environmental factors ...
Source: Reviews in Endocrine and Metabolic Disorders - Category: Endocrinology Source Type: research
Journal of the European Academy of Dermatology and Venereology, EarlyView.
Source: Journal of the European Academy of Dermatology and Venereology - Category: Dermatology Authors: Source Type: research
;rgő Z, Kinyó Á, Rencz F Abstract BACKGROUND: No studies have employed the EuroQoL (EQ-5D) questionnaire to assess health-related quality of life (HRQoL) in pemphigus patients, to date. OBJECTIVES: To evaluate HRQoL of pemphigus patients by the EQ-5D and to analyse the convergent and known-groups validity of the EQ-5D in this patient population. METHODS: Between 2014 and 2017, a multicentre cross-sectional study was carried out. Outcome measures included the five-level EQ-5D (EQ-5D-5L), Dermatology Life Quality Index (DLQI), Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and an a...
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
CONCLUSION: Rituximab is an effective and safe treatment for pemphigus and should be considered earlier in the algorithm of pemphigus treatment. PMID: 29889591 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Source Type: research
Roche announced today that the US Food and Drug Administration (FDA) has approved MabThera/Rituxan ® (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a rare, serious, potentially life-threatening condition characterised by progressive painful blistering of the skin and mucous membranes.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
(MedPage Today) -- FDA approves rituximab (Rituxan) for pemphigus vulgaris
Source: MedPage Today Dermatology - Category: Dermatology Source Type: news
South San Francisco, CA -- June 7, 2018 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan (rituximab) for the treatment of adults with...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Belgium Health | Biotechnology | Clinical Trials | Pemphigus | Pharmaceuticals